share_log

Why SWS Hemodialysis Care's (SHSE:688410) Soft Earnings Are Just The Beginning Of Its Problems

Why SWS Hemodialysis Care's (SHSE:688410) Soft Earnings Are Just The Beginning Of Its Problems

爲什麼SWS透析護理(SHSE:688410)的不佳收益只是其問題的開始
Simply Wall St ·  2024/08/29 19:54

SWS Hemodialysis Care Co., Ltd.'s (SHSE:688410) lackluster earnings announcement last week disappointed investors. We looked deeper and believe that there is even more to be worried about, beyond the soft profit numbers.

SWS Hemodialysis Care有限公司(SHSE:688410)上週發佈的業績低迷的宣告令投資者失望。我們深入研究後發現,除了疲軟的利潤數據之外,還有更多令人擔憂的問題。

1724975682249
SHSE:688410 Earnings and Revenue History August 29th 2024
SHSE:688410盈利和收入歷史數據(2024年8月29日)

Examining Cashflow Against SWS Hemodialysis Care's Earnings

審視SWS Hemodialysis Care的現金流與盈利

In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. You could think of the accrual ratio from cashflow as the 'non-FCF profit ratio'.

在高級財務中,用來衡量公司將報告的利潤轉換爲自由現金流(FCF)的主要比率是應計比率(來自現金流量表)。該應計比率從給定期間的FCF中減去利潤,並將結果除以該時間段內公司的平均營運資產。你可以將應計比率從現金流量表視爲「非自由現金流利潤比率」。

As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

因此,負應計比率對公司是有益的,而正應計比率則是不利的。這並不是說我們應該擔心正應計比率,但值得注意的是應計比率相當高的地方。值得注意的是,有一些學術證據表明,高應計比率通常是短期利潤的不良跡象。

For the year to June 2024, SWS Hemodialysis Care had an accrual ratio of 0.58. As a general rule, that bodes poorly for future profitability. And indeed, during the period the company didn't produce any free cash flow whatsoever. In the last twelve months it actually had negative free cash flow, with an outflow of CN¥26m despite its profit of CN¥106.0m, mentioned above. We saw that FCF was CN¥233m a year ago though, so SWS Hemodialysis Care has at least been able to generate positive FCF in the past. However, that's not all there is to consider. We can see that unusual items have impacted its statutory profit, and therefore the accrual ratio. One positive for SWS Hemodialysis Care shareholders is that it's accrual ratio was significantly better last year, providing reason to believe that it may return to stronger cash conversion in the future. Shareholders should look for improved cashflow relative to profit in the current year, if that is indeed the case.

截至2024年6月,SWS Hemodialysis Care的應計比率爲0.58。根據一般規則,這對未來的盈利能力不利。事實上,在這段時期內,該公司根本沒有產生任何自由現金流。儘管上述提到的其利潤爲CN¥10600萬,但在過去的十二個月中,其實際自由現金流爲負值,流出了CN¥2600萬。然而,一年前其自由現金流爲CN¥23300萬,所以SWS Hemodialysis Care至少過去能夠產生正面的自由現金流。然而,這還沒有考慮到全部因素。我們可以看到,異常項目對其法定利潤和應計比率產生了影響。對SWS Hemodialysis Care股東來說,有一個積極的方面是,去年其應計比率顯著改善,有理由相信它未來可以回到更爲強勁的現金轉換。如果那確實是事實,股東們應該尋求當前年度的現金流相對於利潤的改善。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Given the accrual ratio, it's not overly surprising that SWS Hemodialysis Care's profit was boosted by unusual items worth CN¥16m in the last twelve months. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. If SWS Hemodialysis Care doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

考慮到應計比例,SWS透析護理公司在過去十二個月中受到了價值1600萬人民幣的飛凡項目的推動,這並不讓人感到過於驚訝。我們不能否認,更高的利潤通常讓我們感到樂觀,但我們希望這種利潤能夠持續下去。當我們分析了全球大多數上市公司時,我們發現重大的飛凡項目通常不會重複出現。這一點並不奇怪,因爲項目名稱如此。如果SWS透析護理公司看不到這種貢獻的重複,那麼在其他條件相同的情況下,我們預計其利潤在當前年度會下降。

Our Take On SWS Hemodialysis Care's Profit Performance

對於SWS透析護理公司的利潤表現,我們的看法是

Summing up, SWS Hemodialysis Care received a nice boost to profit from unusual items, but could not match its paper profit with free cash flow. Considering all this we'd argue SWS Hemodialysis Care's profits probably give an overly generous impression of its sustainable level of profitability. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. To help with this, we've discovered 4 warning signs (1 doesn't sit too well with us!) that you ought to be aware of before buying any shares in SWS Hemodialysis Care.

綜上所述,SWS透析護理公司從飛凡項目中獲得了可觀的利潤提升,但無法用自由現金流來匹配其虛擬利潤。考慮到這一切,我們認爲SWS透析護理公司的利潤可能給人們對其可持續盈利能力的印象過於寬容。鑑於此,如果您想對該公司進行更多分析,了解所涉及的風險是至關重要的。爲了幫助您,我們發現了4個警示信號(其中1個對我們來說並不太好!)在購買SWS透析護理公司的股票之前,您應該對此有所了解。

Our examination of SWS Hemodialysis Care has focussed on certain factors that can make its earnings look better than they are. And, on that basis, we are somewhat skeptical. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

我們對SWS透析護理公司的檢查側重於可以使其盈利看起來比實際更好的因素。基於這個基礎,我們對此持有一定的懷疑態度。但是,如果您能夠專注於細枝末節,就會發現還有更多可以發現的。例如,許多人認爲高回報率是良好的商業經濟狀況的指標,而其他人喜歡「跟隨資金」的方式,並尋找內部人員正在購買的股票。雖然這可能需要您進行一些研究,但您可能會發現這個免費的列出高回報率的公司集合或者這個具有重大內部持股的股票列表非常有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論